Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M. Folegatti, Alexander Batten, Christina Dold et al.|The Lancet|2020Cited by 2.6k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trialKatie Ewer, Megan Baker, Jordan R. Barrett et al.|Nature Medicine|2020Cited by 643
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R. Barrett, Catherine Green, Sandra Belij‐Rammerstorfer et al.|Nature Medicine|2020Cited by 340
A blood atlas of COVID-19 defines hallmarks of disease severity and specificityDavid Ahern, Hal Drakesmith, Zhichao Ai et al.|Cell|2022Cited by 327
Differential Antibiotic‐Induced Endotoxin Release in Severe MelioidosisAndrew J. H. Simpson, Nicholas J. White, Steven M. Opal et al.|The Journal of Infectious Diseases|2000Cited by 73